Clinical Trial Update: Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (GEM-AnitoFIRST) is evaluating the efficacy and safety of Anitocabtagene Autoleucel in participants with newly diagnosed multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anitocabtagene Autoleucel (anitocabtagene autoleucel)

Snippet

Sponsor: PETHEMA Foundation | Conditions: De Novo Multiple Myeloma, Anitocabtagene Autoleucel | Phase 2 | Status: RECRUITING